Companies › Lipocine
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brexanolone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Depression, Postpartum; Alzheimer Dementia; PTSD | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05223829 | Brexanolone | Phase 1 | PTSD | Psychiatry | Dec 2025 |
| NCT04838301 | Brexanolone | Phase 2 | Alzheimer Dementia | Neurology | Nov 2026 |
| NCT07822321 | Brexanolone | Phase 3 | Depression, Postpartum | Psychiatry | Aug 2027 |
Cash and short-term investments of $21m on 2026-09-30; operating cash outflow about $10m a year; runway about 27 months at that burn, to Dec 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Xenon Pharmaceuticals Rapport Therapeutics Sichuan Jishengtang Pharmaceutical LB Pharmaceuticals Impax Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.